Thursday, June 18, 2020


According to this article in Review of Optometry:

"high doses of oral riboflavin combined with sunlight can stabilize the cornea similarly to treatment with CXL. One study evaluated topographic corneal changes in three individual cases of patients ingesting 400mg to 800mg of riboflavin supplements daily.1 Researchers observed corneal flattening and improved visual acuity in each case—similar outcomes to CXL."

Monday, June 08, 2020


This study concluded:

multiple dietary supplement containing lutein, astaxanthin, cyanidin-3-glucoside, and DHA has effect to improve accommodative ability and subjective symptoms related to eye fatigue.

Monday, April 13, 2020

Mirtogenol® and Glaucoma


After two months of supplementation with Mirtogenol®, the mean IOP decreased from a baseline of 25.2 mmHg to 22.2 mmHg. Nineteen of the twenty patients taking Mirtogenol had a decreased IOP after three months. No side effects were observed. Ocular blood flow improved.
The results of this study indicate that Mirtogenol® may represent a safe preventative intervention for lowering the risk for developing symptomatic glaucoma by controlling IOP and improving ocular blood flow.

Friday, April 10, 2020

High-tech contact lenses correct color blindness

Researchers have incorporated ultra-thin optical devices known as metasurfaces into off-the-shelf contact lenses to correct deuteranomaly, a form of red-green color blindness. The new customizable contact lens could offer a convenient and comfortable way to help people who experience various forms of color blindness.

Saturday, February 22, 2020

FDA Approves First Contact Lens Indicated to Slow Progression of Myopia in Children

The FDA approved the first contact lens indicated to slow the progression of myopia in children between the ages of 8 and 12 years old at the initiation of treatment. The MiSight contact lens made by CooperVision is a single use, disposable, soft contact lens that is discarded at the end of each day, and is not intended to be worn overnight.
When placed on the eye, one part of the MiSight contact lens corrects the refractive error to improve distance vision in nearsighted eyes, similar to a standard corrective lens. In addition, concentric peripheral rings in the lens focus part of the light in front of the retina (the back of the eye). This is believed to reduce the stimulus causing the progression of myopia.
The trial showed that for the full 3-year period, the progression in myopia of those wearing MiSight lenses was less than those wearing conventional soft contact lenses. 
Three-year peer-reviewed results published in Optometry and Vision Science in August 2019 indicated that use of MiSight 1 day was shown to slow myopia progression 59%.
Generally, myopia first occurs in school-age children and progresses until about age 20.   41.9% of U.S. children ages 5-19 are myopic.9 This is due in part to changing lifestyles, with children spending less time outdoors and more time spent focusing on close objects such as digital screens.
MiSight 1 day will launch in the United States as part of a CooperVision myopia management initiative beginning in March 2020. 

FDA Approves First Treatment for Thyroid Eye Disease

The FDA approved Horizon Therapeutics’ Tepezza (teprotumumab-trbw) for the treatment of adults with thyroid eye disease (TED). The approval represents the first drug approved for the treatment of thyroid eye disease.  
This treatment has the potential to alter the course of the disease, potentially sparing patients from needing multiple invasive surgeries by providing an alternative, non‑surgical treatment option.
Tepezza is a fully human monoclonal antibody (mAb) and a targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R) that is administered to patients once every three weeks for a total of eight infusions.
We expect the average net realized price for a 6-month course of therapy for Tepezza to be approximate $200,000. 
Tepezza was approved based on the results of two studies (Study 1 and 2) consisting of a total of 170 patients with active thyroid eye disease who were randomized to either receive Tepezza or a placebo. Of the patients who were administered Tepezza, 71% in Study 1 and 83% in Study 2 demonstrated a greater than 2 millimeter reduction in proptosis (eye protrusion) as compared to 20% and 10% of subjects who received placebo, respectively.
The most common adverse reactions observed in patients treated with Tepezza are muscle spasm, nausea, alopecia (hair loss), diarrhea, fatigue, hyperglycemia (high blood sugar), hearing loss, dry skin, dysgeusia (altered sense of taste) and headache. Tepezza should not be used if pregnant.

affronEYE® Saffron Extract May Lower Risk of Glaucoma

A new animal study suggests affronEYE saffron could help prevent the onset of glaucoma. The antioxidant and anti-inflammatory characteristics of this potent saffron extract, developed by Pharmactive Biotech Products, S.L., demonstrated an ability to protect retinal cells from damage and death and reduce intraocular hypertension — a key aspect of glaucoma development. 
The study, published in the International Journal of Molecular Sciences on August 2019, demonstrated the neuroprotective and anti-inflammatory effects of Pharmactive’s proprietary hydrophilic saffron extract.
After treatment with AffronEYE, the number of living retinal ganglion cells in the treated group was significantly higher in comparison to the non-treated group. 
AffronEYE’s activities are attributed to its naturally occurring bioactive compounds, specifically crocinsand crocetins. These carotenoids are reported to possess a full spectrum of anti-inflammatory, antioxidative, and neuroprotective properties through their ability to scavenge free oxygen radicals, thus reducing retinal cell damage and cellular self-destruction.
 “Crocins significantly increase the blood flow in the retina,” Mr. Espinel said. “They are believed to improve oxygenation and nutrient supply to retinal structures, serving to slow or completely prevent the development of glaucoma.”


February 2020 - The FDA has granted CooperVision approval for its new Biofinity toric multifocal contact lenses. The product combines the optical designs of CooperVision’s Biofinity toric—the most prescribed toric lens on the market1—and Biofinity multifocal to provide patients with astigmatism and presbyopia vision correction. The company plans to make the lenses available to US eye care professionals later this year, followed by other markets. Lens parameters and other details regarding Biofinity toric multifocal will be made public in the coming months.
This is a huge deal!  Biofinity toric is considered the most stable toric contact lens.  And Biofinity Multifocal provides low, medium, and high adds in either a center distance or center near design.  This lens should be a game changer. 


Alcon announced that Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%) have been approved by the FDA for sale over-the-counter (OTC) in the United States. 
Pataday Once Daily Relief and Pataday Twice Daily Relief are indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander for ages 2 and older. Pataday Twice Daily Relief is also indicated for the temporary relief of red eyes. Since 2008, over 40 million prescriptions have been written for olopatadine, the active ingredient in Pataday.
U.S. commercial availability of Pataday Once Daily Relief and Pataday Twice Daily Relief will begin March 2 in time for the start of spring allergy season, and will be available in all major drug, food and mass market retailers, as well as through online retailers. 

Thursday, October 31, 2019


This article summarizes factors in the environment and diet that influences the progression of myopia.


Some points from this supplementary article in Review of Optometry.

Vitamin A: The blue Mountains Eye study found that elevated beta carotene intake was assoicated with an increased risk of macular degeneration.

Vitamin B2 (riboflavin): Deficiency can cause red eye, photosensitivty, and dry eye.

Vitamin B7 (biotin): deficiency can lead to dry scalp, dandruff, or hair loss.

Vitamin B9 (folate): unmetabolized folic acid can accelerate cardiovascular and ophthalmic vascular disease. 

Vitamin B12 (cobalamin): Provides relief for patients with pernicious anemia, megaloblastic anemia, and sickle cell anemia.

Vitamin C:Assists in collagen fomation and wound healing, including that of the cornea.  Deficiency results in slow healing, frequent infections, low platelets, retinal microaneurysms, and cataracts.

Vitamin D: Crucial for patients facing uveitis/ retinitis, MS, herpes simplex and zoster, neovacularization jin AMD, and patients at risk for diabetes. 

Vitamin E: Increases tear production, retard cataract formation, reduce propensity for diabetic retinopathy.

Magnesium: Deficiency has been linked to retinopathy, acephalgic migraines, twitching eyelids, and glaucoma.

Selenium: Helps protect patients against AMD

Friday, October 18, 2019

Cequa for Dry Eye

Sun Pharmaceutical announced that its dry eye drug Cequa (cyclosporine ophthalmic solution) 0.09% is now commercially available the United States. Cequa, which offers the highest concentration of cyclosporine for ophthalmic use approved by the FDA, is indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye). Cequa is the first and only FDA-approved cyclosporine treatment delivered with nanomicellar (NCELL) technology, which helps to improve the bioavailability and physicochemical stability of cyclosporine, resulting in improved ocular tissue penetration.

Sunday, May 19, 2019


The FDA has approved the use of Eylea, an vascular endothelial growth factor inhibitor (Anti-VEGF) for all stages of diabetic retinopaty. In the past, anti-VEGF medications were injected into the eye only in advanced cases of diabetic retinopathy or in cases of clinically significant macular edema.  This FDA approval suggests anti-VEGF treatment could be utilized in less severe cases of diabetic retinopathy to decrease risk of progression.  We have generally considered diabetic retinopathy to be one of the major causes of preventable blindness in the United States.